Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on the Safety of Abatacept in Relapsing Polychondritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01272856
Recruitment Status : Completed
First Posted : January 10, 2011
Last Update Posted : August 7, 2012
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Stanford Peng, Benaroya Research Institute

Tracking Information
First Submitted Date  ICMJE January 6, 2011
First Posted Date  ICMJE January 10, 2011
Last Update Posted Date August 7, 2012
Study Start Date  ICMJE January 2011
Actual Primary Completion Date May 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 7, 2011)
Incidence of adverse events [ Time Frame: 24 Weeks ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01272856 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 7, 2011)
  • Physician assessment of chondritis burden [ Time Frame: 24 Weeks ]
  • Acute phase reactants (ESR, CRP) [ Time Frame: 24 weeks ]
  • Patient and physician-reported outcome measures, including HAQ, SF-36, and Visual Analogue Scores [ Time Frame: 24 weeks ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study on the Safety of Abatacept in Relapsing Polychondritis
Official Title  ICMJE An Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing Polychondritis
Brief Summary The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
Detailed Description

After a screening period of up to 4 weeks, patients who fulfill all inclusion and exclusion criteria will receive open-label subcutaneous abatacept consisting of 125 mg weekly, beginning 1 week thru Week 24.

Throughout the study, blood will be collected for clinical laboratory safety, pharmacodynamics and biomarkers. Disease activity assessments will include laboratory evaluation of acute phase reactants, pulmonary function testing, computed tomography of the neck and chest, electrocardiogram, echocardiogram, audiogram, physician assessment of chondritis activity, swollen and tender joint counts, and patient- and physican-reported outcomes. Adverse events and concomitant medications will be recorded.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Relapsing Polychondritis
Intervention  ICMJE Drug: Abatacept
125 mg pre-filled syringe for sub-q injection weekly.
Other Name: Orencia
Study Arms  ICMJE Experimental: Open Label Abatacept
Intervention: Drug: Abatacept
Publications * Peng SL, Rodriguez D. Abatacept in relapsing polychondritis. Ann Rheum Dis. 2013 Aug;72(8):1427-9. doi: 10.1136/annrheumdis-2013-203319. Epub 2013 Apr 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 3, 2012)
4
Original Estimated Enrollment  ICMJE
 (submitted: January 7, 2011)
6
Actual Study Completion Date  ICMJE May 2012
Actual Primary Completion Date May 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed Written Informed Consent
  2. Diagnosed with relapsing consisting of 2 major or 1 major + 2 minor criteria as follows:

    • Major criteria

      1. Proven inflammatory episodes involving auricular cartilage
      2. Proven inflammatory episodes involving nasal cartilage
      3. Proven inflammatory episodes involving laryngotracheal cartilage
    • Minor criteria

      1. Ocular inflammation (conjunctivitis, keratitis, episcleritis, uveitis)
      2. Hearing loss
      3. Vestibular dysfunction
      4. Seronegative inflammatory arthritis
    • Active RPC based on at least one of the following:

      • Active chondritis as defined as active inflammation, as observed by the Investigator, in auricular and/or nasal cartilage
      • Active tracheal and/or pulmonary disease documented by abnormal spirometry or chest computed tomography
    • Erythrocyte sedimentation rate ≥ 30 mm/hr or C-reactive protein ≥ 0.6 mg/dL
    • If receiving any of the following medications, has been on a stable dose for the durations indicated without intent to change throughout the study:

      • Azathioprine, methotrexate, mycophenolate, leflunomide: 1 month
      • Corticosteroids: 2 weeks
      • Nonsteroidal anti-inflammatory drugs (NSAIDs): 1 week
  3. Age and Sex

    • Men and women, greater than 18 years of age
    • Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug to minimize the risk of pregnancy.

Women of child bearing age include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:

  • Amenorrhea that has lasted for greater than 12 consecutive months without another cause, or
  • For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.

Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or who are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential.

Women of child bearing age must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of the investigational product.

A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 10 weeks after the last dose of study drug to minimize the risk of pregnancy.

Exclusion Criteria:

  1. Sex and Reproductive Status

    • Women of child bearing age who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study drug.
    • Women who are pregnant or breastfeeding.
    • Women with a positive pregnancy test on enrollment or before administration of abatacept.
  2. Target Disease Exceptions

    • Fulfills American College of Rheumatology criteria for any other connective tissue disease, such as but not necessarily limited to systemic lupus erythematosus, systemic sclerosis (scleroderma), polymyositis or dermatomyositis, or rheumatoid arthritis, or possesses another distinct condition known to be associated with chondritis, such as Wegener's granulomatosis or Behcet's disease
    • Use of cyclophosphamide, cyclosporine A or tacrolimus within one month or at any time during administration of study drug
    • Use of biologic treatments within the timeframes indicated:

      • Anti-CD20 monoclonal antibodies or other immune cell-depleting therapy in the last 6 months or without evidence of appropriate lineage reconstitution
      • TNF antagonists, IL-1R antagonists, or co-stimulation modulators in the last 3 months
      • Any prior treatment with stem cell transplantation or other myeloablative therapy
    • Concomitant illness or disease activity which, in the opinion of the investigator, is likely to require significant additional immunosuppressive therapy (e.g. > 40 mg daily oral prednisone for asthma) during the course of the study
  3. Medical History and Concurrent Diseases

    • Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
    • Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to RPC and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
    • Female subjects who have had a breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory, or other diagnostic evaluations.
    • Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ. Existing non-melanoma skin cell cancers should be removed, the lesion site healed, and residual cancer ruled out before administration of the study drug.
    • Subjects who currently abuse drugs or alcohol.
    • Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
    • Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.
    • Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.
    • Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis, or bronchiectasis).
    • Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be subjects with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
  4. Physical and Laboratory Test Findings

    • Subjects must not be positive for hepatitis B surface antigen.
    • Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
    • Subjects with any of the following laboratory values

      • Hemoglobin < 8.5 g/dL
      • WBC < 3000/mm3 (< 3 x 109/L)
      • Platelets < 100,000/mm3 (< 3 x 109/L)
      • Serum creatinine > 2 times the ULN
      • Serum ALT or AST > 2 times the ULN
    • Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
  5. Allergies and Adverse Drug Reactions

    • Known sensitivity to abatacept
  6. Prohibited Treatments and/or Therapies

    • Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.
    • Any concomitant biologic DMARD, such as anakinra.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01272856
Other Study ID Numbers  ICMJE IRB10063
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Stanford Peng, Benaroya Research Institute
Study Sponsor  ICMJE Benaroya Research Institute
Collaborators  ICMJE Bristol-Myers Squibb
Investigators  ICMJE Not Provided
PRS Account Benaroya Research Institute
Verification Date August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP